Meeting
2014 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma multiforme (GBM).
Authors
Kent C. Shih
Tennessee Oncology, Nashville, TN
Kent C. Shih , Manish R. Patel , Nicholas A. Butowski , Jeffrey A. Bacha , Dennis Brown , William J. Garner , Anne Steino , Richard Stephen Schwartz , Sarath Kanekal , Lorena Lopez , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01478178
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2109)
DOI
10.1200/jco.2014.32.15_suppl.tps2109
Abstract #
TPS2109
Poster Bd #
70A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.
First Author: Kent C. Shih
Poster
2013 ASCO Annual Meeting
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.
First Author: James D. Peyton
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson